Genomewide Meta-Analysis Validates a Role for S1PR1 in Microtubule Targeting Agent-Induced Sensory Peripheral Neuropathy.
Genomewide Meta-Analysis Validates a Role for S1PR1 in Microtubule Targeting Agent-Induced Sensory Peripheral Neuropathy.
复制标题
DOI:
10.1002/cpt.1958
复制
发表时间:
2020-09
影响因子:
6.7
通讯作者:
Kroetz DL
中科院分区:
文献类型:
--
作者:
Chua KC;Xiong C;Ho C;Mushiroda T;Jiang C;Mulkey F;Lai D;Schneider BP;Rashkin SR;Witte JS;Friedman PN;Ratain MJ;McLeod HL;Rugo HS;Shulman LN;Kubo M;Owzar K;Kroetz DL
Microtubule targeting agents (MTAs) are anticancer therapies commonly prescribed for breast cancer and other solid tumors. Sensory peripheral neuropathy (PN) is the major dose-limiting toxicity for MTAs and can limit clinical efficacy. The current pharmacogenomic study aimed to identify genetic variations that explain patient susceptibility and drive mechanisms underlying development of MTA-induced PN. A meta-analysis of genome-wide association studies (GWAS) from two clinical cohorts treated with MTAs (CALGB 40502 and CALGB 40101) was conducted using a Cox regression model with cumulative dose to first instance of grade 2 or higher PN. Summary statistics from a GWAS of European subjects (n = 469) in CALGB 40502 that estimated cause-specific risk of PN were meta-analyzed with those from a previously published GWAS of European ancestry (n = 855) from CALGB 40101 that estimated the risk of PN. Novel single nucleotide polymorphisms in an enhancer region downstream of sphingosine-1-phosphate receptor 1 (S1PR1 encoding S1PR1; e.g., rs74497159, βCALGB 40101 per allele log hazard ratio (95% CI) = 0.591 (0.254 – 0.928), βCALGB 40502 per allele log hazard ratio (95% CI) = 0.693 (0.334 – 1.053); PMETA = 3.62×10−7) were the most highly ranked associations based on P-values with risk of developing grade 2 and higher PN. In silico functional analysis identified multiple regulatory elements and potential enhancer activity for S1PR1 within this genomic region. Inhibition of S1PR1 function in iPSC-derived human sensory neurons shows partial protection against paclitaxel-induced neurite damage. These pharmacogenetic findings further support ongoing clinical evaluations to target S1PR1 as a therapeutic strategy for prevention and/or treatment of MTA-induced neuropathy. NCT00785291 (CALGB 40502) and NCT00041119 (CALGB 40101)
登录
查看更多内容
DOI:
10.1158/1078-0432.ccr-15-0133
发表时间:
2015-10-01
期刊:
Clinical cancer research : an official journal of the American Association for Cancer Research
影响因子:
--
作者:
Komatsu M;Wheeler HE;Chung S;Low SK;Wing C;Delaney SM;Gorsic LK;Takahashi A;Kubo M;Kroetz DL;Zhang W;Nakamura Y;Dolan ME
通讯作者:
Dolan ME
影响因子:
64.8
作者:
Bycroft C;Freeman C;Petkova D;Band G;Elliott LT;Sharp K;Motyer A;Vukcevic D;Delaneau O;O'Connell J;Cortes A;Welsh S;Young A;Effingham M;McVean G;Leslie S;Allen N;Donnelly P;Marchini J
通讯作者:
Marchini J
影响因子:
30.8
作者:
Das, Sayantan;Forer, Lukas;Schoenherr, Sebastian;Sidore, Carlo;Locke, Adam E.;Kwong, Alan;Vrieze, Scott I.;Chew, Emily Y.;Levy, Shawn;McGue, Matt;Schlessinger, David;Stambolian, Dwight;Loh, Po-Ru;Iacono, William G.;Swaroop, Anand;Scott, Laura J.;Cucca, Francesco;Kronenberg, Florian;Boehnke, Michael;Abecasis, Goncalo R.;Fuchsberger, Christian
通讯作者:
Fuchsberger, Christian
DOI:
10.1073/pnas.1820466116
发表时间:
2019-05-21
影响因子:
11.1
作者:
Chen, Zhoumou;Doyle, Timothy M.;Salvemini, Daniela
通讯作者:
Salvemini, Daniela
影响因子:
7.4
作者:
Doolen S;Iannitti T;Donahue RR;Shaw BC;Grachen CM;Taylor BK
通讯作者:
Taylor BK